WST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
WST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
West Pharmaceutical Services's Long-Term Debt for the quarter that ended in Sep. 2024 was $203 Mil.
West Pharmaceutical Services's quarterly Long-Term Debt increased from Mar. 2024 ($73 Mil) to Jun. 2024 ($73 Mil) and increased from Jun. 2024 ($73 Mil) to Sep. 2024 ($203 Mil).
West Pharmaceutical Services's annual Long-Term Debt declined from Dec. 2021 ($209 Mil) to Dec. 2022 ($207 Mil) and declined from Dec. 2022 ($207 Mil) to Dec. 2023 ($73 Mil).
The historical data trend for West Pharmaceutical Services's Long-Term Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
West Pharmaceutical Services Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Long-Term Debt | Get a 7-Day Free Trial | 255.00 | 252.90 | 208.80 | 206.70 | 72.80 |
West Pharmaceutical Services Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Long-Term Debt | Get a 7-Day Free Trial | 152.10 | 72.80 | 72.80 | 72.90 | 202.60 |
West Pharmaceutical Services (NYSE:WST) Long-Term Debt Explanation
Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.
Thank you for viewing the detailed overview of West Pharmaceutical Services's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles Witherspoon | officer: VP & Treasurer | 530 HERMAN O WEST DRIVE, EXTON PA 19341 |
Eric Mark Green | officer: Chief Executive Officer | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Silji Abraham | officer: Chief Digital & Trans Officer | 5000 TOWN CENTER, U, SOUTHFIELD MI 48075 |
Thomas W Hofmann | director | FIVE RADNOR CORPORATE CENTER, SUITE 500, RADNOR PA 19087 |
Chad Winters | officer: VP, CAO & Controller | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Annette F Favorite | officer: Sr. VP Human Resources Officer | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Cindy Reiss-clark | officer: Senior Vice President | 530 HERMAN O. WEST DRIVE, EXTON PA 19341-1147 |
Quintin J Lai | officer: VP Corp Development & Strategy | 530 HERMAN 0. WEST DRIVE, EXTON PA 19341 |
Bernard Birkett | officer: Sr VP, CFO & Treasurer | 1600 WEST MERIT PARKWAY, SOUTH JORDAN UT 84095 |
Stephen H Lockhart | director | C/O NATIONAL RESEARCH CORPORATION, 1245 Q STREET, LINCOLN NE 68508 |
Molly Joseph | director | 9209 GRAND SUMMIT BLVD, DRIPPING SPRINGS TX 78620 |
Kimberly Banks Mackay | officer: SVP, GC & Corporate Secretary | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
George Lloyd Miller | officer: Sr. VP, GC & Corp. Sec. | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
David A Montecalvo | officer: SVP, Glob Ops and Supply Chain | 530 HERMAN O. WEST DRIVE, EXTON PA 19341 |
Robert F Friel | director | 940 WINTER STREET, WALTHAM MA 02451 |
From GuruFocus
By PRNewswire • 10-10-2024
By GuruFocus Research • 08-01-2024
By GuruFocus Research • 07-26-2024
By PRNewswire • 10-07-2024
By PRNewswire • 10-29-2024
By GuruFocus Research • 07-26-2024
By PRNewswire • 05-29-2024
By GuruFocus Research • 06-13-2024
By GuruFocus News • 10-25-2024
By GuruFocus News • 10-26-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.